These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 27270872)

  • 41. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial.
    Ebrahimi-Mameghani M; Sadeghi Z; Abbasalizad Farhangi M; Vaghef-Mehrabany E; Aliashrafi S
    Clin Nutr; 2017 Aug; 36(4):1001-1006. PubMed ID: 27475283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Standardized Nigella sativa seed oil ameliorates hepatic steatosis, aminotransferase and lipid levels in non-alcoholic fatty liver disease: A randomized, double-blind and placebo-controlled clinical trial.
    Khonche A; Huseini HF; Gholamian M; Mohtashami R; Nabati F; Kianbakht S
    J Ethnopharmacol; 2019 Apr; 234():106-111. PubMed ID: 30639231
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers.
    Climax J; Newsome PN; Hamza M; Weissbach M; Coughlan D; Sattar N; McGuire DK; Bhatt DL
    J Am Heart Assoc; 2020 Aug; 9(16):e016334. PubMed ID: 32779505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.
    Asghari S; Asghari-Jafarabadi M; Somi MH; Ghavami SM; Rafraf M
    J Am Coll Nutr; 2018; 37(3):223-233. PubMed ID: 29313746
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.
    Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Hosseinzadeh-Attar MJ; Shakeri A; Asghari-Jafarabadi M; Roshanravan N; Farrin N; Naemi M; Hasankhani M
    Pharmacol Res; 2020 Jun; 156():104770. PubMed ID: 32217148
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial.
    Huang Q; An Z; Xin X; Sun Q; Gao S; Lv S; Xu X; Yang S; Lu F; Yuan J; Zhao Y; Hu Y; Liu P; Feng Q
    BMC Complement Med Ther; 2023 Apr; 23(1):126. PubMed ID: 37076843
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial.
    Saadati S; Sadeghi A; Mansour A; Yari Z; Poustchi H; Hedayati M; Hatami B; Hekmatdoost A
    BMC Gastroenterol; 2019 Jul; 19(1):133. PubMed ID: 31345163
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Portulaca Oleracea (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial.
    Darvish Damavandi R; Shidfar F; Najafi M; Janani L; Masoodi M; Akbari-Fakhrabadi M; Dehnad A
    Phytother Res; 2021 Jun; 35(6):3145-3156. PubMed ID: 33880813
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.
    Chashmniam S; Mirhafez SR; Dehabeh M; Hariri M; Azimi Nezhad M; Nobakht M Gh BF
    Eur J Clin Nutr; 2019 Sep; 73(9):1224-1235. PubMed ID: 30647436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: a randomized controlled pilot trial.
    Korovljev D; Stajer V; Ostojic J; LeBaron TW; Ostojic SM
    Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):688-693. PubMed ID: 30982748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.
    Pervez MA; Khan DA; Ijaz A; Khan S
    Turk J Gastroenterol; 2018 Mar; 29(2):170-176. PubMed ID: 29749323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial.
    He Y; Chen X; Li Y; Liang Y; Hong T; Yang J; Cao Z; Mai H; Yao J; Zhang T; Wu K; Zou J; Feng D
    Am J Clin Nutr; 2024 Jul; 120(1):66-79. PubMed ID: 38795741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized, controlled trial.
    Hosseinabadi S; Rafraf M; Asghari S; Asghari-Jafarabadi M; Vojouhi S
    Complement Ther Med; 2020 Mar; 49():102290. PubMed ID: 32147076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial.
    Darabi Z; Darand M; Yari Z; Hedayati M; Faghihi A; Agah S; Hekmatdoost A
    BMC Res Notes; 2019 Feb; 12(1):89. PubMed ID: 30767788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Curcuminoids Plus Piperine on Glycemic, Hepatic and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind Placebo-Controlled Trial.
    Panahi Y; Khalili N; Sahebi E; Namazi S; Simental-Mendía LE; Majeed M; Sahebkar A
    Drug Res (Stuttg); 2018 Jul; 68(7):403-409. PubMed ID: 29458218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
    Chachay VS; Macdonald GA; Martin JH; Whitehead JP; O'Moore-Sullivan TM; Lee P; Franklin M; Klein K; Taylor PJ; Ferguson M; Coombes JS; Thomas GP; Cowin GJ; Kirkpatrick CM; Prins JB; Hickman IJ
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2092-103.e1-6. PubMed ID: 24582567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol.
    Wicklow B; Wittmeier K; T' Jong GW; McGavock J; Robert M; Duhamel T; Dolinsky VW
    Biochem Cell Biol; 2015 Oct; 93(5):522-30. PubMed ID: 26305052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; Elzehery R; Elhelaly R; Zalata K; Abdelsalam M; Eldeeb AA; Awad M; Elgamal A; Attia A; El-Wakeel N; Eldars W
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1237-1246. PubMed ID: 30096092
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
    Safadi R; Konikoff FM; Mahamid M; Zelber-Sagi S; Halpern M; Gilat T; Oren R;
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2085-91.e1. PubMed ID: 24815326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.